Immix Biopharma, Inc. (IMMX) - Dilution Analysis

8-K filing: Immix Biopharma, Inc. entered into an underwriting agreement to issue and sell 16,778,524 shares of its common stock at a public offering price of $8.94 per share. ($150.0M proceeds)

10-Q filing | 55.4M shares outstanding

S-3 filing: The company is filing an S-3 to register a shelf offering of up to $750,000,000 in common stock, preferred stock, debt securities, warrants, or units.

10-Q filing | 31.9M shares outstanding

8-K filing: Immix Biopharma, Inc. completed a private placement on September 5, 2025, selling 3,831,216 shares of common stock and warrants to purchase 2,873,417 shares, with gross proceeds of approximately $9.1 million. ($9.1M proceeds)

10-Q filing | 30.0M shares outstanding

10-Q filing | 29.7M shares outstanding

10-K filing | 28.3M shares outstanding

10-Q filing | 29.4M shares outstanding

10-Q filing | 28.8M shares outstanding

8-K filing: Immix Biopharma, Inc. completed a merger with its majority-owned subsidiary Nexcella, Inc., issuing 989,876 shares of common stock to former Nexcella stockholders and granting restricted stock awards and options to former participants in the Nexcella 2022 Equity Incentive Plan.

10-Q filing | 26.4M shares outstanding

10-K filing | 26.4M shares outstanding

8-K filing: Immix Biopharma, Inc. entered into an underwriting agreement for an offering of 5,535,055 shares of common stock at a public offering price of $2.71 per share, with the underwriter having an option to purchase an additional 783,970 shares. ($15.0M proceeds)

10-Q filing | 18.6M shares outstanding

S-3 filing: The selling stockholder may offer and resell up to 5,154,737 shares of common stock.

8-K filing: Immix Biopharma, Inc. closed a private placement on August 22, 2023, selling 3,241,076 shares of common stock and pre-funded warrants to purchase 1,913,661 shares, with gross proceeds of approximately $10 million. ($10.0M proceeds)

10-Q filing | 15.0M shares outstanding

10-Q filing | 13.9M shares outstanding

10-K filing | 13.9M shares outstanding

8-K filing: Nexcella, a subsidiary of Immix Biopharma, Inc., entered into share purchase agreements for the purchase of 100,152 shares of Nexcella's common stock at $6.49 per share, for gross proceeds of approximately $650,000. Immediately after the closing, Nexcella has 6,357,444 shares outstanding. ($0.65M proceeds)

S-3 filing: The company intends to offer a combination of common stock, preferred stock, debt securities, and warrants, with an aggregate initial offering price not exceeding $250,000,000.

10-Q filing | 13.9M shares outstanding

10-Q filing | 13.9M shares outstanding

RW filing: The Registrant is requesting the withdrawal of the Registration Statement because the Registrant has decided not to pursue a public offering of its securities at this time due to the availability of other opportunities that the Board of Directors of the Company deemed to be in the best interests of the Company and its shareholders.

S-1 filing: Immix Biopharma, Inc. is offering 1,683,502 shares of its common stock at an assumed public offering price of $2.97 per share.

10-Q filing | 13.8M shares outstanding

10-K filing | 13.9M shares outstanding

8-K filing: Immix Biopharma, Inc. completed its initial public offering on December 20, 2021, selling 4,200,000 shares of its common stock at a price of $5.00 per share. ($21.0M proceeds)

S-1/A filing: This is a firm commitment initial public offering of shares of Immix Biopharma, Inc. common stock.

S-1/A filing: This is a firm commitment initial public offering of shares of Immix Biopharma, Inc. common stock.

S-1/A filing: This is a firm commitment initial public offering of shares of Immix Biopharma, Inc. common stock.

S-1/A filing: This is a firm commitment initial public offering of shares of Immix Biopharma, Inc. common stock.

S-1 filing: This is a firm commitment initial public offering of shares of Immix Biopharma, Inc. common stock.